Answers are grounded in this paper and cite their sources.
Literature review reveals fasting improves endothelial function in patients with autoimmune diseases, suggesting potential cardiovascular benefits.
Intermittent fasting (IF) has emerged as a promising non-pharmacological intervention to mitigate cardiovascular risk and systemic inflammation in patients with autoimmune diseases. This review explores the mechanistic links between IF and improved endothelial function, with a focus on oxidative stress reduction, immune modulation, and metabolic reprogramming. Evidence from in vitro, animal, and early-phase human studies indicates that IF enhances nitric oxide availability, reduces pro-inflammatory cytokines, and promotes vascular protection through ketone body production and autophagy. While benefits such as improved flow-mediated dilation and decreased markers of vascular inflammation have been observed, significant challenges remain regarding the variability of fasting protocols, individual response, and the scarcity of long-term randomized controlled trials. Tailored fasting strategies, supported by omics approaches and circadian alignment, may provide a valuable adjunct in managing cardiovascular complications in autoimmune populations. Further research is essential to clarify the safety, efficacy, and personalization of IF regimens in this context.
No takes yet. Share an insight, caveat, or question.
Al‐Mohammad et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: